Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma

The lack of effective treatment options for advanced non-clear cell renal cell carcinoma (NCCRCC) is a critical unmet clinical need. Applying a high-throughput drug screen to multiple human kidney cancer cells, we identify the combination of the VEGFR-MET inhibitor cabozantinib and the SRC inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Lue, Hui-wen, Derrick, Daniel S., Rao, Soumya, Van Gaest, Ahna, Cheng, Larry, Podolak, Jennifer, Lawson, Samantha, Xue, Changhui, Garg, Devin, White, Ralph, Ryan, Christopher W., Drake, Justin M., Ritz, Anna, Heiser, Laura M., Thomas, George V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149375/
https://www.ncbi.nlm.nih.gov/pubmed/34095877
http://dx.doi.org/10.1016/j.xcrm.2021.100267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149375/
https://www.ncbi.nlm.nih.gov/pubmed/34095877
http://dx.doi.org/10.1016/j.xcrm.2021.100267

Ejemplares similares